Crinetics Pharmaceuticals, INC Schedule 13G passive stakes

Wellington Management Group LLP and its affiliates have filed a Schedule 13G, reporting beneficial ownership of 7,131,084 shares, representing approximately 6.8% of Crinetics Pharmaceuticals, Inc.'s common stock as of June 30, 2026.

FMR LLC and Abigail P. Johnson have updated their Schedule 13G filing, reporting a combined beneficial ownership of 1.4% in Crinetics Pharmaceuticals Inc. common stock as of July 31, 2026.

Farallon Capital Management, L.L.C. and associated entities have reported beneficial ownership of 8.5% of Crinetics Pharmaceuticals, Inc. common stock as of June 30, 2026.

Wellington Management Group LLP and its affiliates have reported beneficial ownership of 7.8% of Crinetics Pharmaceuticals, Inc. common stock as of March 31, 2026.

Driehaus Capital Management LLC has filed an amendment to its Schedule 13G, reporting a decrease in its beneficial ownership of Crinetics Pharmaceuticals, Inc. common stock to 6.11% as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.19% of Crinetics Pharmaceuticals Inc.'s common stock as of March 31, 2026.

The Vanguard Group has filed an amendment to its Schedule 13G, reporting a 0% beneficial ownership in Crinetics Pharmaceuticals Inc. following an internal realignment.

Farallon Capital and its affiliates have filed an amended Schedule 13G for Crinetics Pharmaceuticals, Inc., reporting an 8.5% beneficial ownership and detailing recent management changes within Farallon.

Wellington Management Group LLP and its affiliates reported continued beneficial ownership of 8.9% of Crinetics Pharmaceuticals, Inc.'s common stock as of September 30, 2025.

Farallon Capital Management and its affiliates have reported a collective beneficial ownership of 6% of Crinetics Pharmaceuticals, Inc.'s common stock.

Wellington Management Group and its affiliates have disclosed a 6.2% beneficial ownership stake in Crinetics Pharmaceuticals, Inc. common stock.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a 15.0% beneficial ownership stake in Crinetics Pharmaceuticals Inc. as of March 31, 2025.

The Vanguard Group has filed an amended Schedule 13G, revealing a 10% beneficial ownership stake in Crinetics Pharmaceuticals Inc. as of March 31, 2025.

Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, disclosing a beneficial ownership of 7.49% in Crinetics Pharmaceuticals, Inc. as of December 31, 2024.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a combined beneficial ownership of 10.4% of Crinetics Pharmaceuticals Inc.'s common stock as of January 31, 2025.

FMR LLC and its Chief Executive Officer, Abigail P. Johnson, have reported a beneficial ownership of 9.6% of Crinetics Pharmaceuticals Inc.'s common stock as of December 31, 2024.

The Vanguard Group has filed an amended Schedule 13G, reporting a 9.8% beneficial ownership stake in Crinetics Pharmaceuticals Inc. as of December 31, 2024.